糖尿病肾病病人血浆FABP4水平变化及其与PTEN相关性的研究进展
|
摘要
脂肪细胞型脂肪酸结合蛋白(FABP4)是脂肪酸结合蛋白家族中的一员,对调节糖脂代谢起重要作用,已经成为治疗2型糖尿病(T2DM)及其并发症的潜在靶标。第10号染色体缺失的磷酸酶和张力蛋白同源物基因(PTEN)为一种抑癌基因,可通过负性调控PI3K信号传导途径参与早期糖尿病肾病(DN)的发生、发展。本研究就糖尿病肾病病人血浆FABP4水平变化及其与PTEN的相关性研究进展作一简要综述。
引文
[1]Elmasri H,Karaaslan C,Teper Y,et al.Fatty acid binding protein 4is a target of VEGF and a regulator of cell proliferation in endothelial cells[J].FASEB J,2009,23:3865-3873.
[2]Furuhashi M,Tuncman G,Grgün C,et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J].Nature,2007,447(7147):959-965.
[3]Xu A,Wang Y,Xu JY,et al.Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome[J].Clin Chem,2006,52:405-413.
[4]Furuhashi M,Hotamisligil GS.Fatty acid-binding proteins:role in metabolic diseases and potential as drug targets[J].Nat Rev Drug Discov,2008,7:489-503.
[5]Lee MY,Tse HF,Siu CM,et al.Genomic changes in regenerated porcine coronary arterial endothelial cells[J].Arterioscler Thrombos Vascul Biol,2007,27(11):2443-2449.
[6]Song J,Ren P,Zhang L,et al.Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4[J].Biochem Biophy Res Communi,2010,393(1):89-94.
[7]Makowski L,Boord IB,Maeda K,et al.Lack of macrophage fattyacid-binding protein aP2protects mice deficient in apolipoprotein E against atherosclerosis[J].Nat Med,2001,7:699-705.
[8]张政,彭惠民,徐晓明,等.糖尿病肾病相关微小RNA对高糖下肾小球系膜细胞增殖的影响及其机制[J].中国生物制品学杂志,2010,23(8):821-824.
[9]Virolle T,Adamson ED,Baron V,et al.The Egr-1transcription factor directly activates PTEN during irradiation-induced signaling[J].Cell Biol,2001,3:1124-1128.
[10]Kim SA,Choi HC.Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells[J].Biochem Biophys Res Commun,2012,425:866-872.
[11]中华医学会糖尿病学分会.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):729-801.
[12]Okada M,Takemura T,Yanagida H.Response of mesangial cells to low-density lipoprotein and angiotensinⅡin diabetic(OLETF)rats[J].Kidney Int,2002,61(1):113-124.
[13]Nosadini R,Tonolo G.Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomeru lopathy an tubulointerstitial lesions in type 2diabetes[J].Nutr Metab Cardiovasc Dis,2011,21(2):79-85.
[14]Sasaki H,Kamijo-Ikemori A,Sugaya T,et al.Urinary fatty acids and liver type fatty acid binding protein in diabetic nephropathy[J].Nephron Clin Pract,2009,112:c148-c156.
[15]Young Sun Kang,Dae Ryong Cha.The role of visfatin in diabetic nephropathy[J].Chonnam Medical J,2011,47(3):139-143.
[16]CabréA,Lázaro I,Girona J,et al.Plasma fatty acid-binding protein 4increases with renal dysfunction in type 2diabetic patients without microalbuminuria[J].Clin Chem,2008,54(1):181-187.
[17]Yeung DC,Xu A,Tso AW,et al.Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2diabetic patients[J].Diabetes Care,2009,32(1):132-134.
[18]Toruner F,Altinova AE,Akturk M,et al.The relationship between adipocyte fatty acid binding protein-4,retinol binding protein-4levels and early diabetic nephropathy in patients with type2diabetes[J].Diabetes Res Clin Pract,2011,91(2):203-207.
[19]Furuhashi M.Serum fatty acid-binding protein 4is a predictor of cardiovascular events in end stage renal disease[J].PLoS One,2011,6(11):e27356.
[20]Sommer G,Ziegelmeier M,Bachmann A,et al.Serum levels of adipocyte fatty acid-binding protein(AFABP)are increased in chronic haemodialysis[J].Clin Endocrinol(Oxf),2008,69(6):901-905.
[21]Boden G.Obesity,insulin resistance and free fatty acids[J].Curr Opin Endocrinol Diabetes,2011,18(2):139-143.
[22]Abe H.Recent progress in understanding the molecular pathogenesis of diabetic nephropathy[J].Rinsho Byori,2011,59(2):179-186.
[23]Goldberg RB.Cytokine and cytokine-like inflammation markers,endothelial dysfunction,and imbalanced coagulation in development of diabetes and its complications[J].J Clin Endocrinol Metab,2009,94(9):3171-3182.
[24]Simón I,EscotéX,Vilarrasa N,et al.Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women[J].Obesity(Silver Spring),2009,17(6):1124-1128.
[25]Kralisch S,Stepan H,Kratzsch J,et al.Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus[J].Eur J Endocrinol,2009,160(1):33-38.
[26]邢玲玲,傅淑霞,杨林,等.PTEN在糖尿病肾病患者足细胞损伤中的作用[J].临床与实验病理学杂志,2014,30(12):1375-1378.
[27]Mahimainathan L,Das F,Venkatesan B,et al.Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN[J].Diabetes,2006,55(7):2115-2125.
[28]Gorbenko O,Panayotou G,Zhyvolup A,et al.Identification of novel PTEN-binding partners:PTEN interaction with fatty acid binding protein FABP4[J].Mol Cell Biochem,2010,337(1-2):299-305.
[29]Horie Y,Suzuki A,Kataoka E,et al.Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Investig,2004,113:1774-1783.
[30]Tsuda M,Inoue-Narita T,Suzuki A,et al.Induction of gene encoding FABP4in Pten-null keratinocytes[J].FEBS Lett,2009,583:1319-1322.
[31]皇甫建,徐焱成,李彩萍,等.糖调节受损及初发2型糖尿病患者外周血脂肪细胞型脂肪酸结合蛋白4及人第10号染色体缺失的磷酸酶及张力蛋白同源物水平变化及与胰岛素抵抗的相关性[J].中华糖尿病杂志,2014,6(9):660-664.
[32]Li YY,Xiao R,Huangfu J,et al.Increased plasma levels of FABP4and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus[J].Med Sci Monit,2015,21:426-431.
[33]Aragonès G,Saavedra P,Heras M,et al.Fatty acid-binding protein 4impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells[J].Cardiovascular Diabetology,2012,11:72.
[2]Furuhashi M,Tuncman G,Grgün C,et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J].Nature,2007,447(7147):959-965.
[3]Xu A,Wang Y,Xu JY,et al.Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome[J].Clin Chem,2006,52:405-413.
[4]Furuhashi M,Hotamisligil GS.Fatty acid-binding proteins:role in metabolic diseases and potential as drug targets[J].Nat Rev Drug Discov,2008,7:489-503.
[5]Lee MY,Tse HF,Siu CM,et al.Genomic changes in regenerated porcine coronary arterial endothelial cells[J].Arterioscler Thrombos Vascul Biol,2007,27(11):2443-2449.
[6]Song J,Ren P,Zhang L,et al.Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4[J].Biochem Biophy Res Communi,2010,393(1):89-94.
[7]Makowski L,Boord IB,Maeda K,et al.Lack of macrophage fattyacid-binding protein aP2protects mice deficient in apolipoprotein E against atherosclerosis[J].Nat Med,2001,7:699-705.
[8]张政,彭惠民,徐晓明,等.糖尿病肾病相关微小RNA对高糖下肾小球系膜细胞增殖的影响及其机制[J].中国生物制品学杂志,2010,23(8):821-824.
[9]Virolle T,Adamson ED,Baron V,et al.The Egr-1transcription factor directly activates PTEN during irradiation-induced signaling[J].Cell Biol,2001,3:1124-1128.
[10]Kim SA,Choi HC.Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells[J].Biochem Biophys Res Commun,2012,425:866-872.
[11]中华医学会糖尿病学分会.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):729-801.
[12]Okada M,Takemura T,Yanagida H.Response of mesangial cells to low-density lipoprotein and angiotensinⅡin diabetic(OLETF)rats[J].Kidney Int,2002,61(1):113-124.
[13]Nosadini R,Tonolo G.Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomeru lopathy an tubulointerstitial lesions in type 2diabetes[J].Nutr Metab Cardiovasc Dis,2011,21(2):79-85.
[14]Sasaki H,Kamijo-Ikemori A,Sugaya T,et al.Urinary fatty acids and liver type fatty acid binding protein in diabetic nephropathy[J].Nephron Clin Pract,2009,112:c148-c156.
[15]Young Sun Kang,Dae Ryong Cha.The role of visfatin in diabetic nephropathy[J].Chonnam Medical J,2011,47(3):139-143.
[16]CabréA,Lázaro I,Girona J,et al.Plasma fatty acid-binding protein 4increases with renal dysfunction in type 2diabetic patients without microalbuminuria[J].Clin Chem,2008,54(1):181-187.
[17]Yeung DC,Xu A,Tso AW,et al.Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2diabetic patients[J].Diabetes Care,2009,32(1):132-134.
[18]Toruner F,Altinova AE,Akturk M,et al.The relationship between adipocyte fatty acid binding protein-4,retinol binding protein-4levels and early diabetic nephropathy in patients with type2diabetes[J].Diabetes Res Clin Pract,2011,91(2):203-207.
[19]Furuhashi M.Serum fatty acid-binding protein 4is a predictor of cardiovascular events in end stage renal disease[J].PLoS One,2011,6(11):e27356.
[20]Sommer G,Ziegelmeier M,Bachmann A,et al.Serum levels of adipocyte fatty acid-binding protein(AFABP)are increased in chronic haemodialysis[J].Clin Endocrinol(Oxf),2008,69(6):901-905.
[21]Boden G.Obesity,insulin resistance and free fatty acids[J].Curr Opin Endocrinol Diabetes,2011,18(2):139-143.
[22]Abe H.Recent progress in understanding the molecular pathogenesis of diabetic nephropathy[J].Rinsho Byori,2011,59(2):179-186.
[23]Goldberg RB.Cytokine and cytokine-like inflammation markers,endothelial dysfunction,and imbalanced coagulation in development of diabetes and its complications[J].J Clin Endocrinol Metab,2009,94(9):3171-3182.
[24]Simón I,EscotéX,Vilarrasa N,et al.Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women[J].Obesity(Silver Spring),2009,17(6):1124-1128.
[25]Kralisch S,Stepan H,Kratzsch J,et al.Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus[J].Eur J Endocrinol,2009,160(1):33-38.
[26]邢玲玲,傅淑霞,杨林,等.PTEN在糖尿病肾病患者足细胞损伤中的作用[J].临床与实验病理学杂志,2014,30(12):1375-1378.
[27]Mahimainathan L,Das F,Venkatesan B,et al.Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN[J].Diabetes,2006,55(7):2115-2125.
[28]Gorbenko O,Panayotou G,Zhyvolup A,et al.Identification of novel PTEN-binding partners:PTEN interaction with fatty acid binding protein FABP4[J].Mol Cell Biochem,2010,337(1-2):299-305.
[29]Horie Y,Suzuki A,Kataoka E,et al.Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Investig,2004,113:1774-1783.
[30]Tsuda M,Inoue-Narita T,Suzuki A,et al.Induction of gene encoding FABP4in Pten-null keratinocytes[J].FEBS Lett,2009,583:1319-1322.
[31]皇甫建,徐焱成,李彩萍,等.糖调节受损及初发2型糖尿病患者外周血脂肪细胞型脂肪酸结合蛋白4及人第10号染色体缺失的磷酸酶及张力蛋白同源物水平变化及与胰岛素抵抗的相关性[J].中华糖尿病杂志,2014,6(9):660-664.
[32]Li YY,Xiao R,Huangfu J,et al.Increased plasma levels of FABP4and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus[J].Med Sci Monit,2015,21:426-431.
[33]Aragonès G,Saavedra P,Heras M,et al.Fatty acid-binding protein 4impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells[J].Cardiovascular Diabetology,2012,11:72.